Alinity (Diagnostic Systems)

Alinity is a line of diagnostic systems developed by Abbott. The family includes products used for immunological examination, biochemical and hematological analysis, blood screening, tests for treatment site studies and molecular diagnostics. Devices can work together, which simplifies and optimizes research.

2023: Announcement of the first laboratory system that evaluates traumatic brain injuries by blood test in 18 minutes

On March 7, 2023, Abbott unveiled, according to the developers, the world's first laboratory system to quickly detect concussion from a blood test.

It is noted that every year in the United States alone, millions of people face concussion, but more than half of the victims are never examined. Meanwhile, according to statistics from the Centers for Disease Control and Prevention, more USA than 64,000 Americans died in 2020 due to traumatic brain injuries (). TBI Moreover, people aged 75 years and older are most at risk of receiving TBI, followed by hospitalization and the risk of death.

Abbott Releases First Laboratory System That Evaluates Traumatic Brain Injuries by Blood Test in 18 Minutes

The new Abbott technology involves the use of the Alinity installation. This is a compact system for immunochemical studies, which uses an analytical method based on the reliable chemiluminescent CHEMIFLEX technology, which increases the reliability of the results. The Abbott Alinity i TBI laboratory test allows clinicians to quickly assess the likelihood of a patient's concussion - the system produces a result within 18 minutes. The test measures two biomarkers in the blood that, in elevated concentrations, are closely related to brain damage. Based on the data obtained, doctors can decide on the need for computed tomography and prescribe effective treatment.

According to Abbott, the new method provides results with a sensitivity of 96.7% and a negative predictive value of 99.4%. The test is intended for patients aged 18 years and older with suspected mild traumatic brain injury. The study may be conducted within 12 hours of the incident. A negative test result may eliminate the need for tomography, which will help reduce waiting times for other patients.^[1]

2022: Release of System Test to Identify Four Sexually Transmitted Infections

On May 4, 2022, Abbott announced the release of a test system to simultaneously detect and differentiate common four sexually transmitted infections. The test is carried out on Abbott's state-of-the-art Alinity m high-performance system, which is a laboratory molecular instrument.

Abbott developed its test to simultaneously detect and differentiate four common sexually transmitted infections (STIs): Chlamydia, Gonococcus, Vaginal trichomonada, and Mycoplasma genitalium. Abbott's Alinity m platform uses polymerase chain reaction (PCR) technology, which has high sensitivity in detecting infectious diseases.

Abbott releases test systems to detect four sexually transmitted infections at once

{{quote 'Since 2019, STI cases have increased and we expect rates to rise as people resume testing, delaying it for the duration of the pandemic. In this regard, the need for effective and effective testing is increasing. This four-pack STI test gives healthcare professionals a more holistic picture of a person's health in a single test, helping to create an optimal treatment plan for these common STIs alone or as co-infections, said Abbott Global Director of Science and Innovation Kathryn Becker. }} A first-of-its-kind multiplex test that requires a single smear or urine sample collected at a medical facility or by a doctor at home, according to a press release. The patient himself or a confidant can take his analysis, which will help solve the problem of speed and the growing level of STIs after violations in the provision of medical care during the COVID-19 pandemic led to a decrease in routine screening for STIs.

The main source of STI infection is a sick person. However, often the source can be an outwardly healthy person - the carrier of infection. The transmission path is predominantly sexual. However, a number of diseases, for example, syphilis, scabies, contagious mollusk, can be transmitted as a result of close domestic contact: being in the same bed, using a common towel, washcloths, dishes. For viral hepatitis, in addition to the sexual route of transmission of infection, the injection route also plays an important role, which is typical for drug addicts.^[2]

2020: Alinity m starts selling

In mid-May 2020, Abbott began selling the Alinity m. Among other things, the novelty supports testing for the presence of the coronavirus COVID-19.

Abbott also received emergency approval from regulators for the SARS-CoV-2 IgG serological blood test, which will detect antibodies to coronavirus using another testing platform, Alinity I. In addition, this serological blood test is used in the Architect system.

Abbott began selling a laboratory system that makes 1080 tests in 24 hours. She supports COVID-19

Abbott said it is partnering with hospitals and health systems in the U.S. to install new Alinity m laboratory systems as soon as possible. The company describes it as an advanced molecular diagnostic device - an automated platform that can perform up to 1080 tests in 24 hours. For example, an older m2000 RealTime system from the same company can perform up to 480 tests in 24 hours.

Abbott\reported that running different types of tests on older systems at the same time slows results and/or reduces volume throughput. According to company representatives, Alinity m allows laboratories to conduct any tests for various types of infectious diseases at any time, providing results in less than two hours.

In turn, the Alinity i system is the latest Abbott device for immunoassay. These systems are used worldwide in hospital and academic centers as well as reference laboratories. Abbott said it will send about 30 million coronavirus antibody tests to Architect or Alinity i systems in May, and said it will be able to conduct 60 million tests in June. According to the manufacturer, studies have proven the validity of serological tests conducted on Alinity i, with a specificity of 99.6% and a sensitivity of 100% for patients tested 14 days after the onset of symptoms.^[3]

2017: Start of sales in Europe

On January 10, 2017, Abbott announced the receipt of the European CE Mark Certificate of Conformity for its clinical biochemistry and immunological diagnostic tools for the new Alinity ci series.

CE Mark marks indicate that the product meets European Union quality and safety standards. The presence of such a sign is a necessary condition for the import into the EU countries of a number of products, including medical equipment. Thanks to the passed certification, Alinity ci diagnostic systems can be sold in Europe and some other countries that require the CE Mark quality mark.

Abbott Alinity ci Family Diagnostic Systems

In particular, the Alinity c clinical biochemistry system and the Alinity i immunological diagnostics system will appear on the European market. They can function both separately and in tandem with other Alinity ci series devices.

Improved medicine begins with a high-performance laboratory. The Abbott Alinity family marks an unprecedented approach to creating the most efficient and complete laboratory solution that no competitor can match, "says Abbott Executive Vice President of Diagnostic Products Brian Blaser. - Abbott brings meaningful innovation to diagnostic testing, increasing its role in improving clinical solutions and providing high-quality patient health care.[4]

Notes